Trial · NCT00623623
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
NCT00623623, Phase 3, Completed, Boehringer Ingelheim; results first posted 2019-08-01
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction. Trials, record NCT00623623. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00623623
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
- NCT number
- NCT00623623
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 1,899 participants, actual
- Lead sponsor
- Boehringer Ingelheim
- Conditions
- Myocardial Infarction
- Interventions
- primary PCI, enoxaparin, catheterisation, tenecteplase, clopidogrel
- First posted
- 2008-02-26
- Last updated
- 2019-08-01
- Other registries' IDs
- eudract:2007-001219-44
- Results first posted
- 2019-08-01
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS. | 30 days | The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). |
| Secondary | Number of Patients With All Cause Mortality | 30 days | This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. |
| Secondary | Number of Patients With Cardiac Mortality | 30 days | This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. |
| Secondary | Number of Patients With Cardiogenic Shock | 30 days | This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. |
| Secondary | Number of Patients With Congestive Heart Failure (CHF) | 30 days | This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. |
| Secondary | Number of Patients With Recurrent Myocardial Infarction (Reinfarction) | 30 days | This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported |
| Secondary | Number of Patients With Rehospitalisation for Cardiac Reasons | 30 days | This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported |
| Secondary | Number of Patients With Rehospitalisation for Non-cardiac Reasons | 30 days | This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported |
| Secondary | Number of Patients With Serious Repeat Target Vessel Revascularization | 30 days | This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported |
| Secondary | Number of Patients With All Cause Death and Shock | 30 days | This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes25
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS. | 30 days | Full analysis set (FAS): All consented patients either randomised by Interactive Voice Response System (IVRS) or treated (i.e., manually allocated to treatment group) by the investigator. This population is also referred to as the intention-to-treat population (ITT). | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients With All Cause Mortality | 30 days | FAS | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients With Cardiac Mortality | 30 days | FAS | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients With Cardiogenic Shock | 30 days | FAS | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients With Congestive Heart Failure (CHF) | 30 days | FAS | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients With Recurrent Myocardial Infarction (Reinfarction) | 30 days | FAS | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients With Rehospitalisation for Cardiac Reasons | 30 days | FAS | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients With Rehospitalisation for Non-cardiac Reasons | 30 days | FAS | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients With Serious Repeat Target Vessel Revascularization | 30 days | FAS | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients With All Cause Death and Shock | 30 days | FAS | Participants | COUNT_OF_PARTICIPANTS |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 outcomesResults by group50
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS. | Tenecteplase (Group A) | 116 | Participants | ||
| Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS. | Primary PCI (Group B) | 135 | Participants | ||
| Number of Patients With All Cause Mortality | Tenecteplase (Group A) | 43 | Participants | ||
| Number of Patients With All Cause Mortality | Primary PCI (Group B) | 42 | Participants | ||
| Number of Patients With Cardiac Mortality | Tenecteplase (Group A) | 31 | Participants | ||
| Number of Patients With Cardiac Mortality | Primary PCI (Group B) | 32 | Participants | ||
| Number of Patients With Cardiogenic Shock | Tenecteplase (Group A) | 41 | Participants | ||
| Number of Patients With Cardiogenic Shock | Primary PCI (Group B) | 56 | Participants | ||
| Number of Patients With Congestive Heart Failure (CHF) | Tenecteplase (Group A) | 57 | Participants | ||
| Number of Patients With Congestive Heart Failure (CHF) | Primary PCI (Group B) | 72 | Participants |
1 to 10 of 50Source ClinicalTrials.gov
See all 50 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tenecteplase (Group A) | 950 | |
| Overall Study | STARTED | Primary PCI (Group B) | 949 | |
| Overall Study | COMPLETED | Tenecteplase (Group A) | 949 | |
| Overall Study | COMPLETED | Primary PCI (Group B) | 948 | |
| Overall Study | NOT COMPLETED | Tenecteplase (Group A) | 1 | |
| Overall Study | NOT COMPLETED | Primary PCI (Group B) | 1 |
Source ClinicalTrials.gov
Adverse events250
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Accelerated idioventricular rhythm | Cardiac disorders | Tenecteplase (Group A) | 1 | 949 | |
| serious | Accelerated idioventricular rhythm | Cardiac disorders | Primary PCI (Group B) | 0 | 948 | |
| serious | Angina pectoris | Cardiac disorders | Tenecteplase (Group A) | 1 | 949 | |
| serious | Angina pectoris | Cardiac disorders | Primary PCI (Group B) | 1 | 948 | |
| serious | Angina unstable | Cardiac disorders | Tenecteplase (Group A) | 2 | 949 | |
| serious | Angina unstable | Cardiac disorders | Primary PCI (Group B) | 0 | 948 | |
| serious | Arrhythmia | Cardiac disorders | Tenecteplase (Group A) | 0 | 949 | |
| serious | Arrhythmia | Cardiac disorders | Primary PCI (Group B) | 1 | 948 | |
| serious | Arteriospasm coronary | Cardiac disorders | Tenecteplase (Group A) | 1 | 949 | |
| serious | Arteriospasm coronary | Cardiac disorders | Primary PCI (Group B) | 0 | 948 |
1 to 10 of 250Source ClinicalTrials.gov
See all 250 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Tenecteplase (Group A) | 43 | 949 |
| Total, all-cause mortality | Primary PCI (Group B) | 42 | 948 |
| Total, other adverse events | Tenecteplase (Group A) | 0 | 949 |
| Total, other adverse events | Primary PCI (Group B) | 0 | 948 |
| Total, serious adverse events | Tenecteplase (Group A) | 146 | 949 |
| Total, serious adverse events | Primary PCI (Group B) | 164 | 948 |
Source ClinicalTrials.gov
Papers11
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons27
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With All Cause Death and Shock | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Ischaemic Stroke | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Congestive Heart Failure (CHF) | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Total Stroke (All Types) | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Cardiogenic Shock | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Recurrent Myocardial Infarction (Reinfarction) | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With All Cause Death and Non-fatal Stroke | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Serious Resuscitated Ventricular Fibrillation | Trial comparisons |
1 to 10 of 27
See all 27 trial comparisonsTests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00623623
GET https://conductscience.org/api/trials/v1/NCT00623623/registered?page=2